Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- PMID: 39859516
- PMCID: PMC11765602
- DOI: 10.3390/ijms26020802
Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
Abstract
Prostate cancer, a leading cause of cancer-related mortality among men, often presents challenges in accurate diagnosis and effective monitoring. This systematic review explores the potential of exosomal biomolecules as noninvasive biomarkers for the diagnosis, prognosis, and treatment response of prostate cancer. A thorough systematic literature search through online public databases (Medline via PubMed, Scopus, and Web of science) using structured search terms and screening using predefined eligibility criteria resulted in 137 studies that we analyzed in this systematic review. We evaluated the findings from these clinical studies, revealing that the load of exosomes in the blood and urine of prostate cancer patients, which includes microRNAs (miRNAs), proteins, and lipids, demonstrates disease-specific changes. It also shows that some exosomal markers can differentiate between malignant and benign hyperplasia of the prostate, predict disease aggressiveness, and monitor treatment efficacy. Notably, miRNA emerged as the most frequently studied biomolecule, demonstrating superior diagnostic potential compared to traditional methods like prostate-specific antigen (PSA) testing. The analysis also highlights the pressing need for a standardised analytic approach through multi-centre studies to validate the full potential of exosomal biomarkers for the diagnosis and monitoring of prostate cancer.
Keywords: biomarkers; exosomes; liquid biopsy; miRNA; prognosis; prostate cancer; response.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures




Similar articles
-
The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer.BMC Cancer. 2025 Aug 4;25(1):1264. doi: 10.1186/s12885-025-14505-1. BMC Cancer. 2025. PMID: 40760471 Free PMC article. Review.
-
The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.J Cancer Res Clin Oncol. 2022 Oct;148(10):2893-2910. doi: 10.1007/s00432-022-04213-9. Epub 2022 Aug 4. J Cancer Res Clin Oncol. 2022. PMID: 35922694 Free PMC article. Review.
-
Screening for prostate cancer.Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Cochrane Database Syst Rev. 2013. PMID: 23440794 Free PMC article.
-
Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.Health Technol Assess. 2009 Jan;13(5):iii, xi-xiii 1-219. doi: 10.3310/hta13050. Health Technol Assess. 2009. PMID: 19128541
-
Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review.Mol Cancer. 2016 May 18;15(1):41. doi: 10.1186/s12943-016-0523-5. Mol Cancer. 2016. PMID: 27189160 Free PMC article.
Cited by
-
Crosstalk between exosomes and tumor-associated macrophages in hepatocellular carcinoma: implication for cancer progression and therapy.Front Immunol. 2025 Apr 8;16:1512480. doi: 10.3389/fimmu.2025.1512480. eCollection 2025. Front Immunol. 2025. PMID: 40264760 Free PMC article. Review.
-
Functional tumor-derived exosomes in NSCLC progression and clinical implications.Front Pharmacol. 2025 Mar 19;16:1485661. doi: 10.3389/fphar.2025.1485661. eCollection 2025. Front Pharmacol. 2025. PMID: 40176898 Free PMC article. Review.
-
Methods for Extracellular Vesicle Isolation: Relevance for Encapsulated miRNAs in Disease Diagnosis and Treatment.Genes (Basel). 2025 Mar 12;16(3):330. doi: 10.3390/genes16030330. Genes (Basel). 2025. PMID: 40149481 Free PMC article. Review.
-
Does Machine Learning Prediction of Magnetic Resonance Imaging Prostate Imaging Reporting and Data System Correlate with Target Prostate Biopsy Results?Med Princ Pract. 2025 May 26:1-9. doi: 10.1159/000546509. Online ahead of print. Med Princ Pract. 2025. PMID: 40418923 Free PMC article.
-
Reversing Epigenetic Dysregulation in Neurodegenerative Diseases: Mechanistic and Therapeutic Considerations.Int J Mol Sci. 2025 May 21;26(10):4929. doi: 10.3390/ijms26104929. Int J Mol Sci. 2025. PMID: 40430067 Free PMC article. Review.
References
-
- Ioannidou E., Moschetta M., Shah S., Parker J.S., Ozturk M.A., Pappas-Gogos G., Sheriff M., Rassy E., Boussios S. Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets. Int. J. Mol. Sci. 2021;22:9926. doi: 10.3390/ijms22189926. - DOI - PMC - PubMed
-
- Merriel S.W.D., Pocock L., Gilbert E., Creavin S., Walter F.M., Spencer A., Hamilton W. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20:54. doi: 10.1186/s12916-021-02230-y. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous